This article is more than 5 years old. Information may no longer be current.

Eyetech IPO may launch this month

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eyetech Pharmaceuticals’ initial public offering may occur in the next few weeks, according to investors in the company. Eyetech is in the late stages of development of Macugen, an aptamer that binds to and neutralizes vascular endothelial growth factor, for the treatment of age-related macular degeneration.

Filed on September 16, 2003, Eyetech’s IPO notes that the company plans to offer 6.5 million shares with an estimated target price of $16 to $20 per share. Merrill Lynch and Morgan Stanley are the lead underwriters. The company has a current market capitalization of $731.2 million.

Eyetech licensed the aptamer technology from Gilead Sciences in 2000 and is codeveloping the drug with Pfizer.